---
title: "Hypera S.A. (HYPMY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HYPMY.US.md"
symbol: "HYPMY.US"
name: "Hypera S.A."
industry: "Pharmaceuticals"
datetime: "2026-05-21T17:39:43.154Z"
locales:
  - [en](https://longbridge.com/en/quote/HYPMY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HYPMY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HYPMY.US.md)
---

# Hypera S.A. (HYPMY.US)

## Company Overview

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.hypera.com.br](https://www.hypera.com.br) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: B (0.33)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 17 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.69% |  |
| Net Profit YoY | 122.22% |  |
| P/B Ratio | 1.37 |  |
| Dividend Ratio | 4.81% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3123725361.12 |  |
| Revenue | 1608691924.92 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.00% | B |
| Profit Margin | 19.49% | A |
| Gross Margin | 59.99% | A |
| Revenue YoY | 37.69% | A |
| Net Profit YoY | 122.22% | A |
| Total Assets YoY | 17.36% | A |
| Net Assets YoY | 32.08% | A |
| Cash Flow Margin | 150.02% | B |
| OCF YoY | 37.69% | A |
| Turnover | 0.34 | D |
| Gearing Ratio | 45.68% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hypera S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "37.69%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "122.22%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.81%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3123725361.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1608691924.92",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.00%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "19.49%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "59.99%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "37.69%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "122.22%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "17.36%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "32.08%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "150.02%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "37.69%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.68%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.36 | 22/190 | 21.41 | 19.94 | 17.64 |
| PB | 1.37 | 69/190 | 1.39 | 1.27 | 1.19 |
| PS (TTM) | 2.23 | 61/190 | 2.51 | 2.30 | 2.11 |
| Dividend Yield | 4.81% | 5/190 | 5.88% | 5.20% | 4.36% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HYPMY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HYPMY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HYPMY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HYPMY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**